特宝生物
(688278)
| 流通市值：235.93亿 | | | 总市值：235.93亿 |
| 流通股本：4.08亿 | | | 总股本：4.08亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 936,644,220.25 | 553,161,266.81 | 449,450,206.3 | 528,973,264.73 |
| 交易性金融资产 | 150,003,890.42 | 462,481,948.78 | 376,069,749.2 | 150,590,535.23 |
| 应收票据及应收账款 | 1,156,517,548.8 | 1,243,736,591.74 | 902,743,476.59 | 752,103,323.47 |
| 其中：应收票据 | 211,376,372.33 | 174,560,466.71 | 113,834,547.56 | 116,918,551.61 |
| 应收账款 | 945,141,176.47 | 1,069,176,125.03 | 788,908,929.03 | 635,184,771.86 |
| 预付款项 | 73,907,935.41 | 30,797,005.28 | 77,553,757.53 | 85,322,794.7 |
| 其他应收款合计 | 33,208,430.88 | 21,933,418.95 | 38,987,331.82 | 29,242,224.31 |
| 存货 | 430,807,531.32 | 414,903,686.67 | 374,644,060.24 | 321,192,181.1 |
| 其他流动资产 | 4,149,933.68 | 3,361,124.42 | 15,161,069.39 | 2,255,026.99 |
| 流动资产合计 | 2,785,239,490.76 | 2,730,375,042.65 | 2,234,609,651.07 | 1,869,679,350.53 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 61,652,393.99 | 61,652,393.99 | 56,762,884.93 | 56,762,884.93 |
| 固定资产 | 818,384,456.58 | 831,785,904.63 | 608,598,977.21 | 518,267,612.47 |
| 在建工程 | 140,202,663.8 | 99,706,408.33 | 267,704,214.37 | 249,974,576.13 |
| 使用权资产 | 32,439,854.3 | 35,110,916.57 | 20,638,722.24 | 18,619,834.74 |
| 无形资产 | 344,688,074.9 | 359,231,527.6 | 378,651,120.37 | 294,393,826.7 |
| 开发支出 | 25,590,105.71 | 18,554,618.32 | 9,920,861.34 | 94,002,988.54 |
| 商誉 | 64,475,568.67 | 64,475,568.67 | 64,475,568.67 | - |
| 长期待摊费用 | 41,304,520.75 | 44,839,073.97 | 36,392,792.03 | 13,458,946.41 |
| 递延所得税资产 | 111,192,204.96 | 97,529,151.58 | 79,542,879.49 | 72,211,811.25 |
| 其他非流动资产 | 38,239,630.28 | 30,260,014.23 | 28,950,543.47 | 21,995,262.86 |
| 非流动资产合计 | 1,678,169,473.94 | 1,643,145,577.89 | 1,551,638,564.12 | 1,339,687,744.03 |
| 资产总计 | 4,463,408,964.7 | 4,373,520,620.54 | 3,786,248,215.19 | 3,209,367,094.56 |
| 流动负债: | | | | |
| 短期借款 | 13,423,519.46 | 30,649,004.96 | 19,941,597.21 | 9,904,541.66 |
| 交易性金融负债 | 31,491,773.87 | 31,491,773.87 | 31,749,711.44 | - |
| 应付票据及应付账款 | 103,440,174.1 | 106,467,409.82 | 83,637,196.07 | 87,785,897.27 |
| 应付账款 | 103,440,174.1 | 106,467,409.82 | 83,637,196.07 | 87,785,897.27 |
| 合同负债 | 57,179,085.83 | 55,895,276.82 | 55,463,010.3 | 57,803,454.62 |
| 应付职工薪酬 | 144,136,122.15 | 217,684,681.9 | 152,280,437.78 | 127,393,719.18 |
| 应交税费 | 84,107,777.74 | 121,354,336.5 | 47,889,840.23 | 31,443,277.65 |
| 其他应付款合计 | 132,110,640.14 | 126,638,740.59 | 123,427,695 | 40,298,995.85 |
| 一年内到期的非流动负债 | 15,222,751.86 | 16,829,958.05 | 12,598,042.21 | 5,101,650.92 |
| 其他流动负债 | 189,162.73 | 102,734.32 | 54,480,401.35 | 61,596.9 |
| 流动负债合计 | 581,301,007.88 | 707,113,916.83 | 581,467,931.59 | 359,793,134.05 |
| 非流动负债: | | | | |
| 长期借款 | 135,000,000 | 104,000,000 | 94,000,000 | - |
| 租赁负债 | 23,233,829.71 | 24,491,118.33 | 14,509,100.8 | 14,142,678.24 |
| 预计负债 | 44,424,810.47 | 44,133,602.48 | 40,511,877.04 | 40,171,769.09 |
| 递延收益 | 42,078,919.88 | 36,506,507.8 | 37,219,771.79 | 38,887,491.6 |
| 递延所得税负债 | 6,984,431.24 | 7,696,822.56 | 9,279,607.82 | 985,159.73 |
| 非流动负债合计 | 251,721,991.3 | 216,828,051.17 | 195,520,357.45 | 94,187,098.66 |
| 负债合计 | 833,022,999.18 | 923,941,968 | 776,988,289.04 | 453,980,232.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 408,189,480 | 408,189,480 | 406,800,000 | 406,800,000 |
| 资本公积 | 545,305,143.12 | 528,992,305.35 | 455,257,272.99 | 439,532,136.03 |
| 其他综合收益 | - | - | -81,743.32 | - |
| 盈余公积 | 205,436,611.09 | 205,436,611.09 | 182,952,982.18 | 182,952,982.18 |
| 未分配利润 | 2,471,454,731.31 | 2,306,960,256.1 | 1,964,331,414.3 | 1,726,101,743.64 |
| 归属于母公司股东权益合计 | 3,630,385,965.52 | 3,449,578,652.54 | 3,009,259,926.15 | 2,755,386,861.85 |
| 股东权益合计 | 3,630,385,965.52 | 3,449,578,652.54 | 3,009,259,926.15 | 2,755,386,861.85 |
| 负债和股东权益合计 | 4,463,408,964.7 | 4,373,520,620.54 | 3,786,248,215.19 | 3,209,367,094.56 |
| 公告日期 | 2026-04-29 | 2026-03-27 | 2025-10-23 | 2025-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |